Riga Stradins University signs the cooperation agreement with Grindeks

Riga Stradins University signs the cooperation agreement with Grindeks


On Thursday, 27 November, Riga Stradins University (RSU) and the joint stock company Grindeks will sign the cooperation agreement on cooperation of development of new and innovative pharmaceutical products, closer integration of study programs and practices in accordance to the growth of industry, as well as promotion of the pharmaceutical science development.

The agreement foresees that Grindeks, as far as possible, takes part in the development and implementation of study programs, teaching materials and teaching technology. Cooperation will allow to use the resources of RSU to improve qualifications of the staff of pharmaceutical company, while the company will provide internship for pharmacy students. It is planned that an excellence scholarship fund will be jointly developed. The both sides have also pledged to actively promote the interest of young people in pharmaceutical industry.

Rector Professor of RSU Janis Gardovksis: “As a pharmaceutical education leader, RSU has always emphasised the necessity for universities to cooperate with the industry leaders, as caring for further career opportunities of graduates. The cooperation between the university and industry also allows to develop a potential of science, providing high added value innovative product development, which promotes mutual development and competitiveness in an international scale, by attracting new clients for the company, as well as potential foreign students for the university.”

Chairman of the Board of JSC Grindeks Juris Bundulis: “By signing the cooperation agreement with the Riga Stradins University, Grindeks confirms the importance of the national pharmacy and its will to develop it resolutely. Educating specialists and obtaining new knowledge is a significant factor in growth of any industry, but in the pharmaceutical industry, where plans on organisation of business are conducted for the next 5, 10 and even more years, long-term investment in education is particularly important and sooner or later it will provide good results both for industry and Grindeks. There will always be a need for knowledgable and skilled professionals, that know medicine and the mechanism of action of medication in the pharmaceutical industry, and we are proud to be involved in providing and improvement of such specialists!”

The signing of agreement will be held on Thursday, 27 November at 13.00 in the Rectors Hall of RSU, Dzirciema street 16, D building, 5th floor. Rector Professor of RSU Janis Gardovskis and Chairman of the Board of Grindeks Juris Bundulis, as well as others responsible from both sides for the respective cooperation will participate at the signing.

Jointly signed agreement of RSU and Grindeks is an example of successful cooperation of employers and universities, looking for the most effective solutions for both sides for the exchange of competences and supplement towards the excellence in education. It is sequel for successful cooperation between RSU and Grindeks so far. RSU has already established successful cooperation with other companies and institutions of the industry.

Pharmaceutical studies are one of the eldest and most prestigious studies of RSU. Higher pharmaceutical education, which marked its 90th anniversary in Latvia, is carried out separately for the sixth year in the Faculty of Pharmacy.

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. Grindeks Group consists of 4 subsidiary companies in Latvia, Estonia and Russia; representative offices are opened in 13 countries.

Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. The portfolio of Grindeks products consists of successful combination of branded products and generic medications – including brand products Mildronate® and Ftorafur®, as well as more than 100 effective and safe medications. Currently Grindeks manufactures 25 active pharmaceutical ingredients.

To support and promote growth and education of specialists in engineering, natural sciences, pharmacy and medicine, JSC Grindeks formed a JSC Grindeks fund “For the support of Science and Education” in 2006. Since its existence, the Grindeks fund has awarded scholarships and premiums, as well as supported promotional projects for more than 500 thousand euros.

Additional information:

Laila Klavina
Head of the Communications Department of JSC Grindeks
Ph.: +371 67083370, +371 29256012
E-mail: [email protected]

Related posts